Back to search

Article

Simultaneous inhibition of PI3Kα and EZH1/2 suppresses <i>PIK3CA</i> helical domain mutated CRC by promoting IL15-mediated activation of NK cells

2026-06-17

Abstract excerpt

The PIK3CA gene encodes p110α, the catalytic subunit of phosphoinositide 3-kinase (PI3K), and is among the most frequently mutated oncogenes in multiple cancers, including breast and colorectal cancer (CRC) 1 . Two FDA-approved PI3Kα-specific inhibitors, Alpelisib and Inavolisib, are currently used in combination with fulvestrant to treat hormone receptor-positive (HR+), human epidermal growth factor receptor 2-n...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
e06abd6b-157a-5699-9ed2-3ef34e18f54d
DOI
10.64898/2026.06.16.732619
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Simultaneous inhibition of PI3Kα and EZH1/2 suppresses <i>PIK3CA</i> helical domain mutated CRC by promoting IL15-mediated activation of NK cellsDOI 10.64898/2026.06.16.732619
Select a neighboring publication to make it the new centre.